AbbVie (ABBV) has submitted an application to the US FDA seeking approval for SKYRIZI for subcutaneous (SC) induction for the treatment of adult patients with moderately to severely active Crohn's disease
Importance
Level 1
- Submission supported by data from Phase 3 pivotal AFFIRM study